| Literature DB >> 15246630 |
Darron R Brown1, Kenneth H Fife, Cosette M Wheeler, Laura A Koutsky, Lisa M Lupinacci, Radha Railkar, Gretchen Suhr, Eliav Barr, Anthony Dicello, Weili Li, Judith F Smith, Amha Tadesse, Kathrin U Jansen.
Abstract
A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15246630 DOI： 10.1016/j.vaccine.2003.11.059
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641